Acorda again submits Fampridine-SR for U.S. approval

04/23/2009 | Reuters

Acorda Therapeutics resubmitted its multiple sclerosis drug Fampridine-SR for FDA approval a month after the agency rejected the application because of "format issues." Analysts expect the agency to accept the filing by late June and hand down a decision in February.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC